Skip to main content
SpringerLink
Log in

Quality of Life Outcomes After SBRT

  • Chapter
  • First Online:
Stereotactic Radiosurgery for Prostate Cancer

  • 594 Accesses

Abstract

Although encouraging results in terms of disease control and acute toxicities have been reported with extreme hypofractionation in different prostate SBRT series, the possible impact on health-related quality of life (QoL) of SBRT treatments represents one of the highest research questions and constitutes a central consideration for treatment decision.

By merging physician-reported toxicities and patient-reported outcomes, in the majority of the published series only a transient decline in the urinary and bowel domains was observed within the first 3 months after SBRT, with a complete and durable recovery to baseline or even better within 6 months after SBRT. Comparative analyses between SBRT and other treatment techniques as well as fractionation schedules confirm the modest impact of SBRT on QoL, with only minimal regret rates for patients treated with this modality. Waiting for results of randomized phase III trials, a standardized assessment of QoL and the use of modern SBRT techniques able to minimize radiation-induced toxicities will probably further improve in the next future the QoL impact of this promising treatment modality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Halpern JA, Sedrakyan A, Hsu WC, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer. 2016;122:2496–504.

    Article  Google Scholar 

  2. Fuller DB, Naitoh J, Mardirossian G. Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations. Front Oncol. 2014;4:321.

    PubMed  PubMed Central  Google Scholar 

  3. Katz A, Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol. 2014;9(1):1.

    Article  Google Scholar 

  4. King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877–82.

    Article  Google Scholar 

  5. Hannan R, Tumati V, Xie XJ, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer – results from a multi-institutional clinical trial. Eur J Cancer. 2016;59:142–51.

    Article  Google Scholar 

  6. Bolzicco G, Favretto MS, Scremin E, et al. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat. 2010;9:473–7.

    Article  Google Scholar 

  7. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10(1):1.

    Article  Google Scholar 

  8. Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014;106:dju129.

    Article  Google Scholar 

  9. Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21:1159–64.

    Article  Google Scholar 

  10. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol. 2006;7:903–9.

    Article  Google Scholar 

  11. Sonn GA, Sadetsky N, Presti JC, et al. Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol. 2013;189:S59–65.

    Article  Google Scholar 

  12. Peters LJ, Zagars GK. Neutron therapy in prostate cancer – is the therapeutic ratio improved? Int J Radiat Oncol Biol Phys. 1995;31:204–5.

    Article  CAS  Google Scholar 

  13. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.

    Article  CAS  Google Scholar 

  14. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–32.

    Article  Google Scholar 

  15. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309:814–22.

    Article  CAS  Google Scholar 

  16. Szymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245–50.

    Article  Google Scholar 

  17. Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–57. discussion 64

    Article  CAS  Google Scholar 

  18. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.

    Article  CAS  Google Scholar 

  19. Rhoden EL, Teloken C, Sogari PR, et al. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14:245–50.

    Article  CAS  Google Scholar 

  20. Hanlon AL, Watkins Bruner D, Peter R, et al. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys. 2001;49:51–9.

    Article  CAS  Google Scholar 

  21. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34:585–97.

    Article  CAS  Google Scholar 

  22. Hoskin PJ, Rojas AM, Ostler PJ, et al. Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy. Clin Oncol (R Coll Radiol). 2013;25:321–7.

    Article  CAS  Google Scholar 

  23. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1:1051–9.

    Article  Google Scholar 

  24. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.

    PubMed  Google Scholar 

  25. Jayadevappa R, Malkowicz SB, Wittink M, et al. Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv Res. 2012;47:1902–25.

    Article  Google Scholar 

  26. Barrett B, Brown D, Mundt M, et al. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Mak. 2005;25:250–61.

    Article  Google Scholar 

  27. Skolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite short form. Urology. 2015;85:101–5.

    Article  Google Scholar 

  28. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;2007:16–21.

    Article  Google Scholar 

  29. King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013;87:939–45.

    Article  Google Scholar 

  30. Bhattasali O, Chen LN, Woo J, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol. 2014;9:52.

    Article  Google Scholar 

  31. Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29:2020–6.

    Article  Google Scholar 

  32. Boyer MJ, Papagikos MA, Kiteley R, et al. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. Radiat Oncol. 2017;12:14.

    Article  Google Scholar 

  33. Elias E, Helou J, Zhang L, et al. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy. Radiother Oncol. 2014;112:83–8.

    Article  Google Scholar 

  34. Evans JR, Zhao S, Daignault S, et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015;116:179–84.

    Article  Google Scholar 

  35. Mantz C. A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol. 2014;4:279.

    Article  Google Scholar 

  36. McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118:3681–90.

    Article  Google Scholar 

  37. Quon HC, Musunuru HB, Cheung P, et al. Dose-escalated stereotactic body radiation therapy for prostate cancer: quality-of-life comparison of two prospective trials. Front Oncol. 2016;6:185.

    Article  Google Scholar 

  38. Woo JA, Chen LN, Wang H, et al. Stereotactic body radiation therapy for prostate cancer: what is the appropriate patient-reported outcome for clinical trial design? Front Oncol. 2015;5:77.

    Article  Google Scholar 

  39. Dess RT, Jackson WC, Suy S, et al. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2017;123:1635–42.

    Article  CAS  Google Scholar 

  40. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2010;78:442–8.

    Article  Google Scholar 

  41. Dess RT, Hartman HE, Aghdam N, et al. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018;121(1):61–8.

    Article  CAS  Google Scholar 

  42. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151–7.

    Article  Google Scholar 

  43. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375:1425–37.

    Article  CAS  Google Scholar 

  44. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436–45.

    Article  CAS  Google Scholar 

  45. Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317:1141–50.

    Article  Google Scholar 

  46. Katz A, Ferrer M, Suarez JF, et al. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. Radiat Oncol. 2012;7:194.

    Article  Google Scholar 

  47. Johnson SB, Soulos PR, Shafman TD, et al. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016;121:294–8.

    Article  Google Scholar 

  48. Kim DW, Cho LC, Straka C, et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89:509–17.

    Article  Google Scholar 

  49. Qi XS, Wang JP, Gomez CL, et al. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. Radiother Oncol. 2016;121:113–7.

    Article  Google Scholar 

  50. Gomez CL, Xu X, Qi XS, et al. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015;5:257–62.

    Article  Google Scholar 

  51. Shaverdian N, Verruttipong D, Wang PC, et al. Exploring value from the patient’s perspective between modern radiation therapy modalities for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2017;97:516–25.

    Article  Google Scholar 

  52. Mok G, Benz E, Vallee JP, et al. Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. Int J Radiat Oncol Biol Phys. 2014;90:278–88.

    Article  Google Scholar 

  53. Smeenk RJ, Louwe RJ, Langen KM, et al. An endorectal balloon reduces intrafraction prostate motion during radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:661–9.

    Article  Google Scholar 

  54. Wortel RC, Heemsbergen WD, Smeenk RJ, et al. Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. Int J Radiat Oncol Biol Phys. 2017;99:1243–52.

    Article  Google Scholar 

  55. Chapet O, Udrescu C, Tanguy R, et al. Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;88:425–32.

    Article  CAS  Google Scholar 

  56. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97:976–85.

    Article  Google Scholar 

  57. Zilli T, Jorcano S, Bral S, et al. PV-0552: urethra-sparing SBRT for prostate cancer: acute toxicity results from a randomized phase II trial. Radiother Oncol. 2017;123:S295.

    Article  Google Scholar 

  58. Spratt DE, Lee JY, Dess RT, et al. Vessel-sparing radiotherapy for localized prostate cancer to preserve erectile function: a single-arm phase 2 trial. Eur Urol. 2017;72:617–24.

    Article  Google Scholar 

  59. Gomez-Iturriaga A, Casquero F, Pijoan JI, et al. Health-related-quality-of-life and toxicity after single fraction 19Gy high-dose-rate prostate brachytherapy: phase II trial. Radiother Oncol. 2018;126(2):278–82.

    Article  Google Scholar 

  60. Hoskin P, Rojas A, Ostler P, et al. High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity. Radiother Oncol. 2014;110:268–71.

    Article  Google Scholar 

  61. Morton G, Chung HT, McGuffin M, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. Radiother Oncol. 2017;122:87–92.

    Article  Google Scholar 

  62. Basch E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med. 2014;65:307–17.

    Article  CAS  Google Scholar 

  63. Movsas B, Hunt D, Watkins-Bruner D, et al. Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. Pract Radiat Oncol. 2014;4:187–91.

    Article  Google Scholar 

  64. Johansen MA, Henriksen E, Horsch A, et al. Electronic symptom reporting between patient and provider for improved health care service quality: a systematic review of randomized controlled trials. part 1: state of the art. J Med Internet Res. 2012;14:e118.

    Article  Google Scholar 

  65. Muehlhausen W, Doll H, Quadri N, et al. Equivalence of electronic and paper administration of patient-reported outcome measures: a systematic review and meta-analysis of studies conducted between 2007 and 2013. Health Qual Life Outcomes. 2015;13:167.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland

    Thomas Zilli & Raymond Miralbell

  2. Medical School, Geneva University, Geneva, Switzerland

    Thomas Zilli & Raymond Miralbell

Authors
  1. Thomas Zilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond Miralbell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Zilli .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA

    Michael J. Zelefsky

Ethics declarations

The author and co-authors have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zilli, T., Miralbell, R. (2019). Quality of Life Outcomes After SBRT. In: Zelefsky, M. (eds) Stereotactic Radiosurgery for Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-92453-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92453-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92452-6

  • Online ISBN: 978-3-319-92453-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation